Quest Journals
Journal of Medical and Dental Science Research
Volume 8~ Issue 11 (2021) pp: 43-46
ISSN(Online) : 2394-076X ISSN (Print):2394-0751
www.questjournals.org

Research Paper

Clinico-etiological profile of Diabetes Mellitus among Indian young adults

Dr Alakh Prasad
Managing Director, Patna,Bihar

Background & objectives*: There has been an ascent in the rate of diabetes mellitus in the more youthful populace of India. There are restricted information accessible on the immunological profile of youth beginning diabetes mellitus (DM) particularly in type 2. Hence, this review was attempted to assess the clinical and immunological profile of youth beginning DM in east India.*
Methods*: Fifty-one sequential patients of 8-35 year old enough with diabetes mellitus Center at patna Hospital, India, were remembered for the review. All subjects were tried for glutamic corrosive decarboxylase (GAD), an islet cell antigen ICA512/IA2, and insulin antibodies. Stray and ICA512/IA2 were finished by ELISA and insulin autoantibodies were tried by radioimmunoassay (RIA) technique. These patients were likewise evaluated for hepatitis A to E, cytomegalovirus (CMV) and Epstein-Barr infection (EBV) as trigger components for the beginning of type 1 DM.*
Results*: Of the complete 51 patients, 38 were men and 13 were ladies. The mean age and BMI of the subjects were 19.7 (±7) a long time and 21 (± 5) kg/m2, individually. Twenty patients were underneath the age of 18 yr and their stature was more than the 75th percentile of Indian principles. All patients were suggestive and 12 of these gave ketoacidosis. Just 48% (n=24) were positive for GAD, 14% (n=7) for ICA512/IA-2, and 28% (n=14) were positive for insulin immune response. Five of these patients had proof of hepatitis E infection disease. None of the subjects had proof of dynamic CMV or EBV disease.*
Conclusions*: About a portion of the young beginning diabetes mellitus patients from north India had the presence of pancreatic autoimmunity as GAD, ICA512/IA2, and insulin antibodies or a blend of antibodies reminiscent of having type 1 DM. Further examinations should be done on an enormous example size in various pieces of the country.*
Keywords*: Anti-GAD antibody - HbA_1c - pancreatic autoantibodies - type 1 diabetes mellitus - youth onset diabetes*

Received 08 November, 2021; Revised: 22 November, 2021; Accepted 24 November, 2021

I. Introduction

The commonness of diabetes mellitus (DM) is expanding all through the world, particularly in non-industrial nations, including India because of changing ways of life of individuals and hereditary foundation. Diabetes is excessively higher in the youthful grown-up populace in Asian nations dissimilar to in the West, where it is more normal in more seasoned individuals. In 2012, 371 million individuals in the age bunch 20-79 years were experiencing diabetes with China having the most extreme number followed by India1. It will cause extraordinary monetary weight on wellbeing assets overall particularly in creating countries2. Diabetes in India remembering for a more youthful populace (<25 years) is a disturbing circumstance as a result of its monetary and social effect on society2,3. Studies from India and the USA have shown expanded commonness of diabetes in a more youthful population4,5. In India, 10% of determined patients to have diabetes were under 30 years old enough in 20026. The sorts of diabetes in the young populace from India was arranged into traditional kind 1, old style type 2, ketosis safe youth diabetes, pancreatic diabetes or development beginning diabetes mellitus7. The finding and grouping of diabetes depend on the clinical and immunological profile of the patients. Immunological markers, for example, the pancreatic islet cell antibodies, including insulin antibodies, against GAD, (glutamic corrosive decarboxylase), and hostile to ICA512/IA2, an islet cell antigen are utilized for separation between various kinds of diabetes in the more youthful populace. Prior investigations have detailed clinical profiles and variable rates of immune response energy in youth beginning diabetes mellitus from South Asia8-14. Notwithstanding, none of these investigations has revealed each of the three antibodies together in

youth beginning diabetes mellitus in India. Hereditary foundation inclines an individual to type 1 DM15. Notwithstanding, a trigger factor is needed for the beginning of diabetes. The most widely recognized trigger factor is a viral infection16. There is a scarcity of information on the trigger factor for the beginning of type 1 diabetes in India. Accordingly, the current review was intended to assess clinical and immunological profiles of patients with youth beginning diabetes mellitus patients from north India.

II. Material & Methods

The review subjects were important for the Protégé Encore study, aphase3, randomized, double-blind, global, fake treatment controlled review to assess adequacy and security of Teplizumab (MGA031), an adapted, hostile to CD3 monoclonal immune response, in youngsters and grown-ups with ongoing beginning sort 1 diabetes mellitus17. The review populace in this sub review was chosen from Patna Hospital, India. The enrollment period was from January to July 2010 and test size depended on the number of patients screened at these two places. Members were qualified on the off chance that they met the accompanying models: matured 8-35 years; the weight of somewhere around 36 kg; type 1 diabetes mellitus analyzed for 12 weeks or less, with the need for infused insulin treatment; distinguishable fasting or invigorated C-peptide; and positive autoantibody titre against an islet-cell antigen (ICA-512/IA-2), glutamic corrosive decarboxylase (GAD 65), or insulin, inside 2 weeks of starting insulin treatment. Avoidance standards zeroed in on clinical issues that would conceivably bewilder results or meddle with the safe finish of the preliminary, including genuine cardiovascular problems, dynamic diseases, and late investment in a clinical preliminary, inoculation, or pregnancy. Models for the finding of diabetes were according to standard American Diabetes Association (ADA) guidelines18.

All review patients were exposed to clinical and biochemical tests according to the pre-planned case record structure. The research facility tests included total blood count, blood glucose levels, kidney and liver capacity tests, lipid profile, HbA1c, and pee for miniature HbA1c egg whites. The immunological profile included recognition of antibodies against glutamic corrosive decarboxylase (GAD Ab), a tyrosine phosphatase-like protein (ICA 512/IA-2 Ab) and insulin by ELISA strategy and insulin antibodies were finished by radioimmunoassay (RIA) technique from packs provided by Kronus (Boise, USA). The degrees of three autoantibodies were estimated in an authorized focal research centre (Quintiles Laboratories, Singapore). The remove esteems for GAD Ab, ICA512/IA-2 and insulin antibodies were 5 IU/ml, 15 and 0.4 U/ml, individually. Every one of the three packs was tried for execution capability before concentrating on an example investigation. Alignment confirmation, affectability, accuracy, and weakening check were assessed. The immunological profile for hostile to GAD, against ICA512/IA-2 and insulin antibodies, was done in all patients. The patients having antibodies alone or mixed were considered as experiencing type 1 DM and the leftover patients were delegated type 2 DM.

Further, all patients were tried for dynamic viral contaminations, for example, hepatitis A-E, cytomegalovirus (CMV), and Epstein-Barr infection (EBV) by antigen discovery techniques. Hepatitis An immunizer absolute (hostile to HAV aggregate) and hepatitis An IgM counteracting agent (against HAV, IgM) were tried by Bayer Chemiluminescence. Subjective immunoassay was utilized for the hepatitis screen board (HBsAg, against HCV). Hepatitis B surface antigen (HBsAg) affirmation was tried by Bayer Chemiluminescence. HCV RIBA was finished by National University Hospital (Singapore). Diasorin EIA (compound immunoassay) was utilized for hepatitis D (Delta) neutralizer (against D) location and hepatitis E IgG antibodies were finished by Metropolis (Mumbai, India). Epstein-Barr infection and CMV were tried utilizing polymerase chain response (PCR). IgM and IgG antibodies for EBV and IgG antibodies for CMV were tried in all patients by EIA and safe fluorescence, separately. The institutional morals panel supported the review convention, and all members or gatekeepers gave composed informed assent.

statistical analysis: Data were analyzed using SSPS for windows 10. Statistical methods used were descriptive to calculate mean ± SD.

III. Results

The benchmark attributes of subjects are given in the Table. Of the absolute 51 subjects, 38 were men and 13 were ladies. The mean age was 19.72±7.14 years, and BMI was 21.02±4.57 kg/m2. Twenty subjects were underneath the age of 18 and their tallness was more than the 75th percentile of Indian guidelines. Eleven subjects who were under 18 years old enough had tallness of >75 % percentile according to Indian development diagrams. There was no critical contrast in various boundaries in type 1 and type 2 subjects aside from the age was essentially ($P<0.05$) higher in type 2 gathering. All subjects were indicative of diabetes and 12 of these patients gave ketoacidosis at the hour of determination. The leftover patients gave osmotic side effects. There was no indication of neuropathy, retinopathy, and nephropathy in these patients at the hour of consideration. The mean HbA1c level of all patients was 11.55 per cent. All patients had ordinary blood counts, lipid profiles, and kidney and liver capacity tests. The mean thyroid invigorating chemical (TSH) level was 11.03±36.49 uIU/ml. Just 12% of patients had hypothyroidism.

Anti-GAD Ab was available in 24 (48%) patients. ICA512/IA2 immunizer was recognized in seven (14%) patients, and 14 (28%) patients had insulin antibodies. Seven (14%) patients showed the presence of both enemies of GAD and against ICA512/IA2 antibodies and five (9%) patients had both enemies of GAD and insulin antibodies. The presence of every one of the three pancreatic antibodies was seen in just three patients.

Antibody-positive patients were more youthful, had a lower weight and BMI, and the majority of them gave diabetic ketoacidosis. There was proof of dynamic hepatitis E (IgM counteracting agent positive) disease in five patients. None of the patients showed proof of dynamic CMV, EBV disease or other hepatitis contamination.

IV. Discussion

The separation somewhere in the range of T1DM and T2DM is troublesome in youthful patients yet should be possible by immunological markers, as an enemy of GAD, ICA512/IA2, and insulin antibodies19. In our review, against GAD antibodies were available in 48% of patients, ICA512/IA2 counteracting agent in 14% and insulin immune response in 28% instances of youth beginning diabetes. Further, dynamic viral contamination, particularly HEV as a potential trigger factor for the beginning of T1DM was seen in just 10% of cases

Autoimmunity in youth beginning has been accounted for before from India and elsewhere11-13. The degree of autoimmunity announced in the current review was among the most elevated revealed so far contrasted with other Indian studies7-9. Kouchipillai et al6 have shown 38% enemy of GAD energy in their review. Nonetheless, Pan et al20 announced predominance as low as 9% in South Indian patients13. A review from north India has shown higher qualities, for example, 70% of GAD inspiration and 20-26 percent energy of ICA neutralizer in type1diabetic patients20. Goswami et al7 have detailed 24.2 percent pancreatic neutralizer in youth beginning diabetes patients from north India. Different investigations, for example, by Tica et al21 and Thai et al22 have announced 27 and 39.6 percent inspiration against GAD, individually. Lan et al23 announced 54.6 percent energy against GAD and 24 percent for both enemies of GAD and ICA512/IA2 antibodies. The presence of each of the three antibodies was seen in just three patients. None of the examinations has investigated all antibodies together for the conclusion of type1diabetes. In our review, hostile to GAD immune response was available in all counteracting agent positive youth beginning DM. Thusly, testing for hostility to GAD Abalone may maybe do the trick as a demonstrative device in youth beginning DM.

One more fascinating reality with regards to our review was that five diseases. None of the patients showed proof of late EBV and CMV infection diseases. There are something like two diverse pathogenic components in infection instigated diabetes: cytolytic contamination of beta cells prompting their annihilation, and setting off of autoimmunity prompting the immune system interceded obliteration of beta cells24. Something like 10 infections has been involved as setting off factors at the beginning of T1DM. Retrovirus, mumps infection, rubella infection, CMV, enterovirus and EBV are answerable for immune system intervened annihilation of beta cells. Other viral contaminations, for example, encephalomyocarditis infection, Coxsackie B infections can prompt direct harm to beta cell25-29. In our review, just five patients had proof of HEV disease proposing its conceivable job at the beginning of immune system DM in youth. Hepatitis C infection contamination has been displayed to play a part in the advancement of T1DM30-31. In any case, one more review didn't discover any connection between any of the viral hepatitis contaminations and the beginning of DM32.

In this review, the stature of T1DM patients was more than 75% percentile of the Indian norm. The increment in stature might be credited to immune system marvel working in development speed increase just as creation in antibodies in T1DM33.

Our review had specific restrictions. We have not done HLA-composing in this review. Further, there was a choice predisposition as we avoided subjects with indications of insulin resistance.

V. Conclusions

All in all, the presence of pancreatic antibodies was seen among half of the young beginning diabetic patients from north India, hostile to GAD Ab being the most well-known. Comparable examinations ought to be done in different pieces of the country with an enormous example size.

References

[1]. IDF Diabetes Atlas, update 2012. International Diabetes Federation. Available from: *http://www.idf.org/ diabetesatlas/5e/Update2012*.

[2]. Ramachandran A, Das AK, Joshi SR, Yajnik CS, Shah S, Prasanna Kumar KM. Current status of diabetes in India and need for novel therapeutic agents. *J Assoc Physicians India* 2010; *58* : 7-9.

[3]. Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R, *et al*. ICMR-INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical 5Research–INdia DIABetes (ICMR-INDIAB) study. *Diabetologia* 2011; *54* : 3022-7.

[4]. Pettitt DJ, Talton J, Dabelea D, Divers J, Imperatore G, Lawrence JM, *et al*. SEARCH for Diabetes in Youth Study Group. Prevalence of diabetes in U.S. youth in 2009: the SEARCH for diabetes in youth study. *Diabetes Care* 2014; *37* : 402-8.

[5]. Kochupillai N, Goswami R. Youth-onset diabetes in India: nature of diabetes and use of bovine insulin in their treatment. *RssDI textbook of diabetes*, April 2002. Available from: *www. iddtindia.org/youth.asp*.

[6]. Goswami R, Kochupillai N, Gupta N, Kukreja A, Lan M, Maclaren NK. Islet cell autoimmunity in youth onset diabetes mellitus in Northern India. *Diabetes Res Clin Pract* 2001; *53* : 47-54.

[7]. Baruah MP, Ammini AC, Khurana ML. Demographic, breast- feeding, and nutritional trends among children with type 1 diabetes mellitus. *Indian J Endocrinol Metab* 2011; *15* : 38-42.

[8]. Jyotsna VP, Singh SK, Gopal D, Unnikrishnan AG, Agrawal NK, Singh SK, *et al*. Clinical and biochemical profiles of young diabetics in North-Eastern India. *J Assoc Physicians India* 2002; *50* : 1130-4.

[9]. Katulanda P, Shine B, Katulanda GW, Silva A, Asfir EL, Sheriff R, *et al*. Diabetes mellitus among young adults in Sri Lanka-role of GAD antibodies in classification and treatment: The Sri Lanka Young Diabetes study. *Diabetologia* 2008; *51* : 1368-74.

[10]. Amutha A, Datta M, Unnikrishnan IR, Anjana RM, Rema M, Venkat Narayan KM, et al. Clinical profile of diabetes in the young seen between 1992 and 2009 at a specialist diabetes centre in south India. Prim Care Diabetes 2011; 5 : 223-9.

[11]. Thai AC, Mohan V, Khalid BA, Cockram CS, Pan CY, Zimmet P, et al. The ASDIAB Study Group. Islet autoimmunity status in Asians with young-onset diabetes (12-40 years): association with clinical characteristics, beta cell function and cardio- metabolic risk factors. Diabetes Res Clin Pract 2008; 80 : 224-30.

[12]. Unnikrishnan AG, Bhatia E, Bhatia V, Bhadada SK, Sahay RK, Kannan A, et al. Type 1 diabetes versus type 2 diabetes with onset in persons younger than 20 years of age. Ann N Y Acad sci 2008; 1150 : 239-44.

[13]. Mohan V, Deepa R, Bhatia E, Singh AK, Hitman GA, Zimmet PZ, et al. Antibodies to pancreatic islet cell antigens in diabetes seen in Southern India with particular reference to fibrocalculous pancreatic diabetes. Diabet Med 1998; 15 : 156-9.

[14]. Mehra NK, Kumar N, Kaur G, Kanga U, Tandon N. Biomarkers of susceptibility to type 1 diabetes with special reference to the Indian population. Indian J Med Res 2007; 125 : 321-44.

[15]. Galleri L, Sebastiani G, Vendrame F, Grieco FA, Spagnuolo I, Dotta F. Viral infections and diabetes. Adv Exp Med Biol 2012; 771 : 252-71.

[16]. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, et al. Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378 : 487-97.

[17]. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20 : 1183-97.

[18]. Pan CY, So WY, Khalid BA, Mohan V, Thai AC, Zimmet P, et al. Metabolic, immunological and clinical characteristics in newly diagnosed Asian diabetes patients aged 12-40 years. Diabet Med 2004; 21 : 1007-13.

[19]. Mehra NK, Kumar N, Kaur G, Kanga U, Tandon N. Biomarkers of susceptibility to type 1 diabetes with special reference to the Indian population. Indian J Med Res 2007; 125 : 321-44.

[20]. Tica V, Hanif MW, Andersson A, Valsamakis G, Barnett AH, Kumar S, et al . Frequency of latent autoimmune diabetes in adults in Asian patients diagnosed as type 2diabetes inet al. Metabolic, immunological and clinical characteristics in newly diagnosed Asi Birmingham, United Kingdom. Ann N Y Acad sci 2003; 1005 : 356-8.

[21]. Thai AC, Ng WY, Loke KY, Lee WR, Lui KF, Cheah JS. Anti-GAD antibodies in Chinese patients with youth and adult-onset IDDM and NIDDM. *Diabetologia* 1997; *40* : 1425-30.

[22]. Lan MS, Wasserfall C, Maclaren NK, Notkins AL. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. *Proc Natl Acad sci UsA* 1996; *93* : 6367-70.

[23]. Yoon JW, Ihm SH, Kim KW. Viruses as a triggering factor of type 1 diabetes and genetic markers related to the susceptibility to the virus-associated diabetes. *Diabetes Res Clin Pract* 1989; *7* (Suppl 1) : S47-58. Jun HS, Yoon JW. A new look at viruses in type 1 diabetes. *Diabetes Metab Res Rev* 2003; *19* : 8-31.

[24]. Salminen K, Sadeharju K, Lönnrot M, Vähäsalo P, Kupila A, Korhonen S, *et al*. Enterovirus infections are associated with the induction of beta-cell autoimmunity in a prospective birth cohort study. *J Med Virol* 2003; *69 :* 91-8.

[25]. Lönnrot M, Korpela K, Knip M, Ilonen J, Simell O, Korhonen S, *et al*. Enterovirus infection as a risk factor for β-cell autoimmunity in a prospectively observed birth cohort: The Finnish Diabetes Prediction and Prevention Study. *Diabetes* 2000; *49* : 1314-8.

[26]. Roivainen M, Rasilainen S, Ylipaasto P, Nissinen R, Ustinov J, Bouwens L, *et al*. Mechanisms of coxsackievirus-induced damage to human pancreatic beta-cells. *J Clin Endocrinol Metab* 2000; *85* : 432-40.

[27]. Blomqvist M, Juhela S, Erkkilä S, Korhonen S, Simell T, Kupila A, *et al*. Rotavirus infections and development of diabetes-associated autoantibodies during the first 2 years of life. *Clin Exp Immunol* 2002; *128* : 511-5.

[28]. Chen LK, Chou YC, Tsai ST, Hwang SJ, Lee SD. Hepatitis C virus infection-related Type 1 diabetes mellitus. *Diabet Med* 2005; *22* : 340-3.

[29]. Uto H, Matsuoka H, Murata M, Okamoto T, Miyata Y, Hori T, *et al*. A case of chronic hepatitis C developing insulin-dependent diabetes mellitus associated with various autoantibodies during interferon therapy. *Diabetes Res Clin Pract* 2000; *49* : 101-6.

[30]. Atabek ME, Kart H, Erkul I. Prevalence of hepatitis A, B, C and E virus in adolescents with type-1 diabetes mellitus. *Int J Adolesc Med Health* 2003; *15* : 133-7.

[31]. Songer TJ, LaPorte RE, Tajima N, Orchard TJ, Rabin BS, Eberhardt MS, *et al*. Height at diagnosis of insulin dependent diabetes in patients and their non-diabetic family members. *Br Med J (Clin Res Ed)* 1986; *292* : 1419-22.